LPTX News and Press, Leap Therapeutics Inc. From 07/08/22

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due t...

Positive results using DKN-01 plus chemotherapy for the treatment of patients with metastatic castration-resistant prostate cancer were presented at ASCO 2022 medical conference. The global prostate cancer market could reach $12 billion by 2025. Positive initial results using DKN-...

Leap Therapeutics to Host Virtual R&D Day on July 12, 2022 Leap Therapeutics to Host Virtual R&D Day on July 12, 2022 PR Newswire CAMBRIDGE, Mass. , June 27, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company ...

Leap Therapeutics to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting PR Newswire CAMBRIDGE, Mass. , May 26, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (...

Gainers: Harpoon Therapeutics (HARP) +18%. Grove (GRVI) +11%. NanoViricides NNVC +11%. Travere Therapeutics TVTX +9%. Compass Therapeutics (CMPX) +4%. Losers: Chimerix CMRX -58%. Eliem Therapeutics ELYM -29%. Humacyte (HUMA) -20%. Va...

Leap Therapeutics press release (NASDAQ:LPTX): Q1 GAAP EPS of -$0.09 beats by $0.01. Cash and cash equivalents totaled $103.2 million at March 31, 2022. Shares +2.73% PM. For further details see: Leap Therapeutics GAAP EPS of -$0.09 beats by $0.01

Leap Therapeutics Reports First Quarter 2022 Financial Results PR Newswire CAMBRIDGE, Mass. , May 13, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, toda...

3 Penny Stocks for Your Late-April 2022 Watchlist What are the best penny stocks to buy in 2022? This is a question that many investors are asking as we continue to barrel through an extremely volatile period in the stock market. And while there are many factors to consider when trying ...

Leap Therapeutics press release (NASDAQ:LPTX): Q4 GAAP EPS of -$0.10 beats by $0.01. Revenue of $0.38M (flat Y/Y) beats by $0.08M. CEO comment: "Following our public offering, we are well funded to advance DKN-01 into the next stages of development in G/GEJ and other cancers, and we look forw...

Leap Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results PR Newswire CAMBRIDGE, Mass. , March 11, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeut...